Use of single dose low-molecular-weight heparin in long hemodialysis

International Journal of Artificial Organs

Volumn 21, Issue 4, 1998, Pages 196-200

  Lai, K N ^a   Ho, K ^b   Li, M ^a   Szeto, C C ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti factor Xa; Dosage; Hemodialysis; Low molecular weight heparin

Indexed keywords

COAGULATION; HEMODIALYZERS; MOLECULAR WEIGHT; POLYSACCHARIDES;

ANTI-COAGULATION; ANTI-FACTOR XA; DOSAGE; DOSE EQUIVALENT; FACTOR XA; HAEMODIALYSIS; LONG DURATION; LOW-MOLECULAR WEIGHT HEPARINS; SINGLE-DOSE; TIME INTERVAL;

DIALYSIS;

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; PARTIAL THROMBOPLASTIN TIME;

EID: 0031841562     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889802100404     Document Type: Article

References (18)

1. Ljunberg B. A low molecular weight fraction as an anticoagulant during hemodialysis. Clin Nephrol 1985; 24: 15-20.
2. Schrader J, Valentin R, Tonnis JH, et al. Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney Int 1985; 28: 823-9.
3. Anastassiades EG, Lane DA, Flynn A, Curtis JC. Preliminary evaluation of repeated use of a low MW heparin in hemodialysis for chronic renal failure. Proc Euro Dial Transplant 1985; 22: 329-33.
4. Grau E, Siguenza F, Maduell F, et al. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron 1992; 62:13-7.
5. Nurmohamed MT, Ten Cate J, Stevens P, Hoek JA, Lins RL, Ten Cate JW. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. ASAIO Trans 1991; 37: M459-61.
6. Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JC. A low-molecular -weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Nephrol Dial Transplant 1990; 5: 135-40.
7. Hirsh J. Low molecular weight heparin. Blood 1992; 79: 1-17.
8. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
9. Fraxiparine: Technical brochure. Sanofi Pharma, Gentilly Cedex, 1995: 73-8.
10. Lai CKW, Polosa R, Holgate ST. Effect of 15-(s)-hydroxyeico-satetraeoic acid on allergen-induced asthmatic responses. Am Rev Respir Dis 1990; 141: 1423-7.
11. Schrader J, Stibbe W, Armstrong VW, et al. Comparison of low molecular-weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-6.
12. Lane DA, Flynn A, Ireland H, Anastassiades E, Curtis JR. On the evaluation of heparin and low molecular weight heparins in hemodialysis for chronic renal failure. Haemostasis 1986; 16 (suppl 2): S38-47.
13. Lai KN, Wang AYM, Ho K, Szeto CC, Li M, Wong LKS, Yu AWY. Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis 1996; 28: 721-6.
14. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500.
15. Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 20: 219-24.
16. Doutremepuich C, Bousquet F, Gestreau GL, Toulemonde F, Bayrou B. Comparative study on the effects of a low molecular weight heparin (CY216) and standard heparin in low dosage on experimental venous thrombosis. Haemostasis 1987; 17: 201-5.
17. Fraxiparine: Technical brochure. Sanofi Pharma, Gentilly Cedex, 1995; 8-28.
18. Guilbaud J, Carsin H, Braquet M, Houin G, Mersch GM. Pharmacokinetic study of CY 216 in burned patients. In: Breddin K, Fareed J, Samama M, eds. Fraxiparine; First International Symposium, New York, Stuttgart: Schattauer 1989; 85-6.